Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations and further to its earlier intimation dated April 16, 2025, in respect of a patent infringement dispute with Astellas Pharma, Inc., Astellas Ireland Co., and Astellas Pharma Global Development, Inc. (collectively ‘Astellas’) in relation to its product ‘Mirabegron’, Lupin has informed that the Company and its wholly owned subsidiary Lupin Pharmaceuticals, Inc., USA, have entered into a Settlement and License Agreement (‘Agreement’) with Astellas. Under the terms of the Agreement, Lupin will pay Astellas (1) USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027. The settlement terms are confidential. This settlement resolves Lupin’s pending litigation with Astellas and allows Lupin to continue to sell its Mirabegron product.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: